Viking Therapeutics IncVKTX
▲ PositiveTechnologyCapitalrelevance
Advancement of VK2735 into large late-stage trials and start of Phase 1 trial for VK3019 highlight obesity pipeline progress.
Impact on assets 1
Biotech & Genomic Medicine
Viking Therapeutics IncTheme Impact 1
Off-coverage companies
Related news
China
Hong Kong SAR China▲
3SBio Signs MindRank AI Deal to Commercialize Oral GLP-1 Obesity Drug MDR-001
3SBio subsidiaries Zhejiang Sunshine Mandi and Zhejiang Wansheng have signed an agreement with MindRank AI to commercialize MDR-001, an oral GLP-1 candidate in Phase 3 obesity trials. The deal lands as 3SBio shares trade at HK$15.07, with a 1-year total shareholder return down 45.58 percent, a 30-day share price return down 6.69 percent and a year-to-date share price return down 38.69 percent, even as the 3-year total shareholder return is up more than 2x. On valuation, 3SBio trades at a P/E of 3.9x against a Hong Kong Biotechs industry average of 17.3x and a peer group average of 36.2x, with an estimated fair P/E of 8.2x. A discounted cash flow model puts 3SBio's estimated future cash flow value at HK$33.62 versus the current HK$15.07 share price. Recent declines in revenue and net income, combined with the weak 1-year return, could pressure sentiment if MDR-001 progress disappoints.
About megatrends
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Technology
Longevity & Life Extension › GLP-1 Healthspan Proxies Technology
1530.HK · Demand · Positive 3SBio subsidiaries signed a deal with MindRank AI to commercialize the Phase 3 oral GLP-1 obesity candidate MDR-001, expanding its obesity drug pipeline.
MindRank AI Ltd · Demand · Positive MindRank AI signed the agreement with 3SBio to commercialize its oral GLP-1 candidate MDR-001.
603010.CG · Demand · Positive Zhejiang Wansheng is named as a 3SBio subsidiary signing the agreement to commercialize MDR-001.
Zhejiang Sansheng Wandi Pharmaceutical · Demand · Positive Zhejiang Sunshine Mandi is named as a 3SBio subsidiary signing the agreement to commercialize MDR-001.
United States▲2
Eli Lilly's Taltz Plus Zepbound Shows Added Psoriasis and Metabolic Benefit in Phase 3b Trial
An exploratory analysis of Eli Lilly's ongoing phase 3b TOGETHER-PsO trial indicates that combining Taltz, or ixekizumab, with Zepbound, or tirzepatide, may improve both psoriasis and metabolic outcomes compared with Taltz alone. The trial enrolled patients with moderate-to-severe plaque psoriasis who were obese or overweight and who had at least one additional weight-related comorbid condition, randomizing them to receive Taltz plus Zepbound or Taltz alone. At week 36, participants who took the two treatments together saw better changes in psoriasis-specific, immune, and metabolic biomarkers than those in the Taltz monotherapy group, with changes noted in more psoriasis disease-associated and metabolic biomarkers. The trial's primary endpoint is the proportion of participants achieving both Psoriasis Area and Severity Index 100 and at least 10% weight reduction at week 36. Lilly noted that in the US, approximately 61% of individuals with psoriasis also have obesity or are overweight with at least one weight-related comorbidity.
About megatrends
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Technology
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▲Technology
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Technology
LLY · Technology · Positive Phase 3b TOGETHER-PsO analysis shows Taltz plus Zepbound improves psoriasis and metabolic biomarkers versus Taltz alone.
DenmarkUnited States
United Kingdom3impact 4
Novo Nordisk Raises 2026 Outlook, Targets Peer-Level Growth Through 2030
Novo Nordisk raised its 2026 outlook while telling investors at a London strategy day that it aims to grow revenue through 2030 at roughly the pace of large drugmaker peers. In the second quarter of 2026, adjusted sales rose 7% at constant exchange rates and adjusted operating profit rose 11%, though reported operating profit fell 16%, dragged down by a DKK 6.3 billion non-cash impairment on pipeline assets and by a year-ago rebate reversal. The raised 2026 outlook now puts adjusted sales and operating profit between flat and down 6% at constant exchange rates, while the longer view promises more than five multi-blockbuster launches by 2030, over DKK 150 billion in pipeline sales in 2035, and revenue growth in line with peers from 2026 to 2030, which management stressed are ambitions rather than guidance. The company's Wegovy pill topped 265,000 weekly prescriptions in a single week this summer and total prescriptions have passed 5 million since launch, but Eli Lilly's Mounjaro and Zepbound have overtaken Ozempic and Wegovy in the US, and Novo's next-generation shot CagriSema missed its goal of proving it was not inferior to Lilly's tirzepatide. At a forward P/E of 10.97 as of October 6, against 18.77 for the sector and a five-year average of 27.91, Novo trades well below peers, with 59 hedge funds holding the stock in the most recent quarter, up from 55, and short interest at just 0.83% of the float.
About megatrends
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
Aging Population › Chronic-Disease Pharma Franchises Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies Competition
NVO · Capital · Neutral Novo raised its 2026 outlook and reported Q2 adjusted sales +7% and operating profit +11%, but reported operating profit fell 16% on a DKK 6.3bn impairment and the outlook still implies flat-to-down adjusted sales/profit.
NVO · Competition · Negative Eli Lilly's Mounjaro and Zepbound have overtaken Ozempic and Wegovy in the US, and Novo's next-gen CagriSema missed its non-inferiority goal versus Lilly's tirzepatide.
LLY · Competition · Positive Eli Lilly's Mounjaro and Zepbound have overtaken Ozempic and Wegovy in the US, and CagriSema missed its non-inferiority goal versus Lilly's tirzepatide.
United States▲impact 4
Eli Lilly Trades at 30.94 Times Forward Earnings Despite 48% Revenue Growth
Eli Lilly reported 48% revenue growth for the second quarter of 2026 and raised its full-year outlook, yet the stock trades at 30.94 times forward earnings, well below its five-year average of 45.59. Mounjaro brought in $9.9 billion in the quarter, up 91%, and Zepbound added $4.9 billion, up 46%, while non-GAAP gross margin reached 86.3% and revenue outside the US rose 80% to $8.6 billion. The once-daily weight-loss pill Foundayo booked $98 million in its first quarter of sales, and Medicare's new coverage pathway now lets eligible patients get Foundayo or Zepbound for $50 a month, with Lilly estimating about 20 million Medicare patients may meet the clinical criteria. Management lifted 2026 revenue guidance to between $85 billion and $87 billion from $82 billion to $85 billion, and plans to file retatrutide with the FDA in the first quarter of 2027. Growth was volume-led, with volume up 60% against a 13% decline in realized prices, and second-quarter EPS of $8.38 absorbed $3.03 per share of acquired research charges, while reported EPS was $7.94 and full-year guidance stands at $35.50 to $36.50.
About megatrends
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Demand
Aging Population › Chronic-Disease Pharma Franchises ▲Demand
Longevity & Life Extension › GLP-1 Healthspan Proxies ▲Demand
LLY · Capital · Positive Lilly reported 48% Q2 revenue growth, 86.3% gross margin, and raised full-year 2026 revenue guidance to $85-87B.
LLY · Demand · Positive Mounjaro sales rose 91% to $9.9B, Zepbound rose 46% to $4.9B, and Medicare's new coverage pathway opens Foundayo/Zepbound to ~20M eligible patients.
United States▲
Eli Lilly Consensus Estimates Rise as Zacks Rank Holds at #3
Eli Lilly is expected to post earnings of $9.83 per share for the current quarter, a year-over-year change of +40%, with the Zacks Consensus Estimate edging up +0.1% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $36.64 points to a change of +51.3% from the prior year and has risen +0.3% over the past month, while the next fiscal year's consensus estimate of $46.8 indicates a change of +27.7% and has moved +1.4% higher. On the revenue side, the consensus sales estimate of $22.14 billion for the current quarter points to a year-over-year change of +25.8%, with the $88.88 billion and $102.02 billion estimates for the current and next fiscal years indicating changes of +36.4% and +14.8%, respectively. In the last reported quarter, Lilly posted revenues of $22.97 billion, up +47.7% year over year, and EPS of $8.38 versus $6.31 a year ago, beating the Zacks Consensus revenue estimate of $20.26 billion by +13.38% and the EPS estimate by +39.43%. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Lilly, and the stock is graded D on the Zacks Value Style Score, indicating it trades at a premium to its peers.
About megatrends
Aging Population › Chronic-Disease Pharma Franchises ▲Capital
Longevity & Life Extension › GLP-1 Healthspan Proxies Capital
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Capital
LLY · Capital · Positive Consensus earnings and revenue estimates for Eli Lilly rose, with current-quarter EPS seen up 40% YoY and full-year EPS up 51.3%.
United StatesDenmark▲
Novo Nordisk Gets FDA Review Update on Denecimig as New CagriSema Data Land
Novo Nordisk reported an FDA review update for its haemophilia A therapy denecimig, including manufacturing-related feedback, in October 2026. The FDA has kept the denecimig review open without giving a new action date, flagging manufacturing issues rather than problems with the FRONTIER efficacy or safety data, though Novo Nordisk says the extended review does not change its 2026 financial outlook. The pharmaceutical group also presented new CagriSema data on brain and metabolic pathway effects in obesity and diabetes at EASD 2026, alongside real-world evidence comparing clinical outcomes for semaglutide with tirzepatide in everyday practice. Novo Nordisk, a US based pharmaceuticals group with a market value of about DKK1.1 trillion, focuses on treatments for chronic conditions such as diabetes, obesity and blood disorders. The key signposts ahead are the EMA decision following the positive CHMP opinion for denecimig and the US FDA decision on the CagriSema obesity filing expected in the fourth quarter of 2026.
About megatrends
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▲Regulation
Longevity & Life Extension › GLP-1 Healthspan Proxies Regulation
NVO · Regulation · Neutral FDA kept the denecimig haemophilia A review open, flagging manufacturing issues with no new action date, though efficacy/safety data were not the problem.
NVO · Technology · Positive New CagriSema data on brain and metabolic pathway effects in obesity and diabetes were presented at EASD 2026, alongside positive CHMP opinion for denecimig.